Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Recently granted patents

New US pharmaceutical patent grants from the past 12 months — competitive surveillance for BD and IP teams.

Patents
890

Quick answer

890 pharmaceutical patents in our USPTO index were granted within the past year. Browse by grant date with links to applicant company portfolios and related drug profiles.

  1. WO 2026039538

    MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS

    TRISHULA THERAPEUTICS INC [US] · Granted Thu Feb 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026039321

    MÉTHODES DE TRAITEMENT DU CANCER DE LA PROSTATE

    AMGEN INC [US] · Granted Thu Feb 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2026039512

    INHIBITEURS DE KRAS

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu Feb 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2026039306

    BÉTAÏNE ET FOLATE POUR FAVORISER LA MATURATION DU CERVEAU D'UN NOURRISSON

    ABBOTT LAB [US] · Granted Thu Feb 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 20260042800

    ANTIMICROBIAL PEPTIDOMIMETICS

    BASILEA PHARMACEUTICA INT AG ALLSCHWIL [CH] · Granted Thu Feb 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 07 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2026035787

    MACROCYLES DE PROTÉASE DE TRAITEMENT SPÉCIFIQUE DE L'UBIQUITINE (USP1)

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu Feb 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 07 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2026033380

    PROCESSUS DE PRÉPARATION DE COMPLEXES OLIGOSACCHARIDIQUES

    BIONTECH SE [DE] · Granted Thu Feb 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 07 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. WO 2026033885

    POLYTHÉRAPIE FAISANT INTERVENIR DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET AGENTS STABILISANT OU AUGMENTANT L'EXPRESSION DE CLDN18.2

    ASTELLAS PHARMA INC [JP] · Granted Thu Feb 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 07 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2026032865

    SEL D'UN INHIBITEUR DE SOS-1

    BAYER AG [DE] · Granted Thu Feb 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 07 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. EP 4691463

    VERFAHREN ZUR PRÄVENTION ODER BEHANDLUNG VON HERZVERSAGEN BEI EINEM PATIENTEN MIT (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDIN-3-CARBOXAMID

    BAYER AG [DE] · Granted Wed Feb 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Feb 06 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2026027375

    HYDROXY-DIHYDROPYRIDINON CARBOXAMIDE ALS SCHÄDLINGSBEKÄMPFUNGSMITTEL

    BAYER AG [DE] · Granted Thu Feb 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. WO 2026027669

    BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB

    ALFASIGMA SPA [IT] · Granted Thu Feb 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2026027695

    COMPOSITIONS ET PROCÉDÉS

    BIONTECH SE [DE] · Granted Thu Feb 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 20260035439

    Anti-Sars-COV-2 Antibodies and Uses Thereof

    ABBVIE INC [US] · Granted Thu Feb 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. WO 2026027759

    AGENTS ET MÉTHODES POUR UNE ADMINISTRATION CIBLÉE À DES CELLULES

    BIONTECH SE [DE] · Granted Thu Feb 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 20260035358

    WEE1 DEGRADING COMPOUNDS AND USES THEREOF

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu Feb 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 20260034134

    TREATMENT OF CANCER WITH METASTASES IN THE CENTRAL NERVOUS SYSTEM

    BOEHRINGER INGELHEIM INT [DE] · Granted Thu Feb 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. WO 2026029046

    LIPIDE D'URÉE OU DE CARBAMATE AYANT UN GROUPE CYCLIQUE DANS UNE CHAÎNE LATÉRALE, NANOPARTICULES LIPIDIQUES DE CELUI-CI ET COMPOSITION PHARMACEUTIQUE ASSOCIÉE

    ASTELLAS PHARMA INC [JP] · Granted Thu Feb 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. WO 2026030375

    NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

    GENZYME CORP [US] · Granted Thu Feb 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. WO 2026024938

    MÉTHODES DE RÉDUCTION DE LA TRANSMISSION INTRA-UTÉRINE D'UNE INFECTION À SALMONELLA DUBLIN

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Thu Jan 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. WO 2026025082

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOGEN MA INC [US] · Granted Thu Jan 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. WO 2026021698

    PARTICULE D'ACIDE NUCLÉIQUE

    BIONTECH SE [DE] · Granted Thu Jan 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 20260027049

    AVACOPAN FORMULATIONS

    AMGEN INC [US] · Granted Thu Jan 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12533358

    Methods of treatment with elinzanetant

    BAYER CONSUMER CARE AG [CH] · Granted Tue Jan 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 22 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. NO 2026007

    Serplulimab

    ACCORD HEALTHCARE S L U [ES] · Granted Thu Jan 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 17 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. WO 2026017827

    COMPOSÉS DE CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE PKMYT1

    ASTRAZENECA AB [SE] · Granted Thu Jan 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 17 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. WO 2026020076

    MÉTHODE DE TRAITEMENT DU PRURIGO NODULAIRE

    AMGEN INC [US] · Granted Thu Jan 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 17 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. EP 4681704

    NEUE FORMULIERUNGEN VON PITOLISANT

    BIOPROJET PHARMA [FR] · Granted Wed Jan 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Jan 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. WO 2026015882

    FRAGMENTS D'ANTIGÈNE HSV ET PROCÉDÉS ASSOCIÉS

    BIONTECH SE [DE] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. WO 2026013161

    VACCINATION DE PREMIÈRE IMMUNISATION ET DE RAPPEL POUR LE TRAITEMENT ET LA PRÉVENTION D'INFECTIONS PROVOQUÉES PAR LE VIRUS DE LA GRIPPE AVIAIRE CHEZ LES AVIENS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. WO 2026015857

    COMPOSITION DE VACCIN DESTINÉE À DÉCLENCHER UNE RÉPONSE DES LYMPHOCYTES T CD8+ SPÉCIFIQUE DE L'EBV

    BIONTECH SE [DE] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 20260015393

    NOVEL NMU RECEPTOR 2 AGONISTS

    BOEHRINGER INGELHEIM INT [DE] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. WO 2026015429

    BONBONS GOMMEUX À COMPRESSION DIRECTE

    BAYER HEALTHCARE LLC [US] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. WO 2026015433

    PRÉPARATION IN SITU DE COMPOSITIONS GOMMEUSES EN BLISTER

    BAYER HEALTHCARE LLC [US] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. WO 2026013162

    VECTEUR VACCINAL DU VIRUS HERPÈS DU DINDON POUR LE TRAITEMENT ET LA PRÉVENTION D'INFECTIONS PROVOQUÉES PAR LE VIRUS DE LA GRIPPE AVIAIRE CHEZ DES DINDONS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. WO 2026013287

    DÉRIVÉS DE QUINAZOLINE UTILISÉS EN TANT QU'ANTAGONISTES DE GIPR

    ASTRAZENECA AB [SE] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. WO 2026013310

    COMPOSITION PHARMACEUTIQUE LIQUIDE À BASE DE STIRIPENTOL

    BIOCODEX [FR] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. WO 2026013643

    PROCÉDÉS ET COMPOSITIONS POUR CONCEVOIR DES CHAÎNES D'ÉPITOPES AVEC DES LIEURS

    BIONTECH SE [DE] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. WO 2026015039

    THÉRAPIE GÉNIQUE POUR LE TRAITEMENT DE L'ENCÉPHALOPATHIE ÉPILEPTIQUE ASSOCIÉE À LA SYNGAP1

    BIAL PORTELA & CA SA [PT] · Granted Thu Jan 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 20260008777

    INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu Jan 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. WO 2026011019

    COMPOSÉS PYRROLIDINYLE UTILISÉS EN TANT QU'INHIBITEURS DE CGAZ

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu Jan 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. WO 2026007889

    COMPOSITION IMMUNOGÈNE CONTRE LE SOUS-TYPE H7 ET LE SOUS-TYPE H5 DU VIRUS DE LA GRIPPE AVIAIRE

    BOEHRINGER INGELHEIM VETMEDICA CHINA CO LTD [CN] · Granted Thu Jan 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. WO 2026008525

    FORMULATIONS STABLES CONTENANT DES RADIONUCLÉIDES

    BAYER AG [DE] · Granted Thu Jan 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. WO 2026007886

    COMPOSITION IMMUNOGÈNE CONTRE LE SOUS-TYPE H7 DU VIRUS DE LA GRIPPE AVIAIRE

    BOEHRINGER INGELHEIM VETMEDICA CHINA CO LTD [CN] · Granted Thu Jan 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. WO 2026010917

    FORMULATIONS NUTRITIONNELLES PERMETTANT DE MAINTENIR DES MICROBIOTE ET FONCTION INTESTINAUX SAINS

    ABBOTT LAB [US] · Granted Thu Jan 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. WO 2026007883

    COMPOSITION IMMUNOGÈNE CONTRE LE SOUS-TYPE H7 DU VIRUS DE LA GRIPPE AVIAIRE

    BOEHRINGER INGELHEIM VETMEDICA CHINA CO LTD [CN] · Granted Thu Jan 08 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. WO 2026006803

    COMPOSÉS À NOYAU À 5 CHAÎNONS UTILISÉS EN TANT QUE MODULATEURS DE L'HÉLICASE D'ADN RECQ DU SYNDROME DE WERNER ET LEURS UTILISATIONS

    AMGEN INC [US] · Granted Fri Jan 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu Dec 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. WO 2026006805

    COMPOSÉS À NOYAU À 6 CHAÎNONS UTILISÉS COMME MODULATEURS DE L'HÉLICASE À ADN RECQ DU SYNDROME DE WERNER ET LEURS UTILISATIONS

    AMGEN INC [US] · Granted Fri Jan 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu Dec 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How recent are these patent grants?

This hub lists published patents with a grant date within the last 365 days, ordered newest first.

Which patent classes are included?

We index USPTO PatentsView records with pharmaceutical CPC classifications A61K and A61P linked to tracked assignee companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.